Sanofi, Novo Nordisk roll out new promos for pens

Share this article:
Sanofi-Aventis US is rolling out a consumer campaign for its Lantus SoloStar pen aimed at getting people with type 2 diabetes to think differently about insulin.

Dubbed “I Chose,” the effort is launching with print ads and a website ( TV ads will launch later in the year, as will social media components. Euro RSCG Life is handling creative.

The key insight behind the campaign, said Charlene Leitner, senior director, diabetes marketing at Sanofi-Aventis US, was that negative impressions of insulin impede many sufferers from getting the treatment they need.

“Many are fearful even to start insulin, so they just avoid going on it when they may not have an A1C level that's in control” said Leitner. “

The website features testimonials from patients who overcame their reluctance to use insulin to manage their diabetes.

Meanwhile, Novo Nordisk launched an online photo contest to promote its FlexPen, inviting users to submit photos showing the paces they've taken the device. In keeping with the franchise's racing theme, the grand prize is a trip to the Firestone Indy Lights Championship Race in Miami, FL.

Users can submit their pics at through July 18, and visitors to the site can vote on contest entries between August 8 and August 29.

There's also a Race Charlie Kimball game and video featuring the racecar driver, who has type 1 diabetes and drives the No. 26 Levemir FlexPen car.

Creative for the campaign was handled by Big Communications, while PR was handled by Marina Maher Communications.
Share this article:

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.